Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Akouos, Inc. (AKUS)

13.29   0 (0%) 11-30 16:00
Open: 13.2 Pre. Close: 13.29
High: 13.33 Low: 13.16
Volume: 1,790,496 Market Cap: 0(M)

Technical analysis

as of: 2023-01-06 4:29:05 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 15.61     One year: 15.88
Support: Support1: 13    Support2: 10.81
Resistance: Resistance1: 13.37    Resistance2: 13.6
Pivot: 13.24
Moving Average: MA(5): 13.28     MA(20): 13.28
MA(100): 7.75     MA(250): 6
MACD: MACD(12,26): 0.3     Signal(9): 0.5
Stochastic oscillator: %K(14,3): 64.2     %D(3): 54.5
RSI: RSI(14): 71.3
52-week: High: 13.6  Low: 2.31
Average Vol(K): 3-Month: 669 (K)  10-Days: 496 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ AKUS ] has closed below upper band by 30.6%. Bollinger Bands are 91.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 13.32 - 13.39 13.39 - 13.44
Low: 13.1 - 13.2 13.2 - 13.27
Close: 13.16 - 13.3 13.3 - 13.41

Company Description

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Headline News

Thu, 01 Dec 2022
Lilly Completes Acquisition of Akouos Expanding Efforts to Help ... - Investors | Eli Lilly and Company

Mon, 14 Nov 2022
10 Most Promising Gene Therapy Companies to Watch - Yahoo Finance

Tue, 18 Oct 2022
Lilly to Acquire Akouos - citybiz

Tue, 18 Oct 2022
Eli Lilly to buy gene therapy company Akouos for $487 mln - Reuters

Tue, 18 Oct 2022
Lilly to Acquire Akouos to Discover and Develop Treatments for ... - Investors | Eli Lilly and Company

Tue, 27 Sep 2022
Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 37 (M)
Shares Float 19 (M)
% Held by Insiders 1.1 (%)
% Held by Institutions 104.8 (%)
Shares Short 828 (K)
Shares Short P.Month 2,280 (K)

Stock Financials

EPS -2.83
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.9
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -22.3
Return on Equity (ttm) -42.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.45
Qtrly Earnings Growth 0
Operating Cash Flow -74 (M)
Levered Free Cash Flow -60 (M)

Stock Valuations

PE Ratio -4.7
PEG Ratio -0.2
Price to Book value 2.71
Price to Sales 0
Price to Cash Flow -6.63

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.